Archived Bulletins

November 07, 2018

Published: November 07, 2018
Category: Trials
Trial Activation: REC.4 (EA8143)
The CCTG trial REC.4 (EA8143), A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) has been centrally activated.
 
If you have questions please contact the study coordinator: Max Sherry
 
Read More

Published: November 07, 2018
Category: Trials
The CCTG SRC1 (ACOSOG Z9007) A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST) has been permanently closed and no further ethics approvals or folow up data are required.
Read More

Published: November 07, 2018
Category: Trials
The purpose of this memorandum is to provide an update on the Investigator requirement to complete Protection of Human Research Participant Training. As of September 26th 2018, the NIH Office of Extramural Research (OER) no longer offer the current free Protecting Human Research Participant (PHRP) training course and will not offer an alternative.
Read More

Published: November 07, 2018
Category: Trials
Trial Closure: PR.15
The PR.15  trial, a Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer has been  permanently closed and no further ethics approvals or folow up data are required.
Read More

Published: November 07, 2018
Category: News
Aldo Del Col recognized with Meritorious Service Medal
Congratulations to Aldo Del Col who is a CCTG Lay Committee Representative and valued member of the Hematology Disease Site Committee, he is ensuring that the patient voice is part of the design and conduct of . He has turned his prognosis into an opportunity to make a difference
 
Read More

Published: November 07, 2018
Category: Publications
Publication: LY.15

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study (ONLINE). Leuk Lymphoma 1-8, 2018.

Read More

October 24, 2018

Published: October 24, 2018
Category: Trials

MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

The randomization of the first MA.39 patient has been completed by the Juravinski Cancer Centre at Hamilton Health Sciences on October 16, 2018 - Congratulations! This site is lead by the Study Chair Tim Whelan and has four additional patients registered.

Read More

Published: October 24, 2018
Category: Trials
Closed to accrual: CCTG SRC.6

The CCTG SRC.6 (COG ARST1321) study is now closed to accrual.

Thanks to the hard work of many across the CCTG group and collaborative working processes with our pediatric colleagues the SRC.6 trial met its primary endpoint early. Addition of pazopanib to preoperative chemoradiation increased rates of complete pathological response for individuals with sarcoma.  Additional follow up is planned to determine if this translates into improved event free and overall survival. A huge thank you to everybody who contributed to this success.

Read More